AstraZeneca reports boost in cancer drug sales

LONDON — Anglo-Swedish drugmaker AstraZeneca is reporting its first quarterly sales in years on the back of new cancer treatments.

The company said Friday that product sales rose 4 percent in the fourth quarter to $5.49 billion, buoyed by new drugs such as bladder cancer treatment Imfinzi, and lymphoma medication Calquence.

It was the first increase since the third quarter of 2014.

AstraZeneca says it expects product sales to increase "in the low single digits" this year.

Despite encouraging news on the sales front, net income fell 29 percent to $1.3 billion. Core operating profit, which excludes restructuring and acquisition-related costs to give a better picture of underlying performance, fell 12 percent to $1.79 billion.

CEO Pascal Soriot says the sales increase shows AstraZeneca is "steadily turning a corner."

You may also interested in

Aid groups warn of crisis as Mongolia hit by...

Dec 21, 2016

Another unusually harsh winter in Mongolia that's decimating livestock and sending temperatures to...

China starts 2017 engulfed by smog, issues...

Jan 2, 2017

Beijing and other cities across northern and central China are shrouded in thick smog, prompting...

China begins to ease its 2,000-year-old monopoly...

Jan 3, 2017

China has started an overhaul of its salt industry, easing a monopoly that has existed in some form...

Asian shares mixed as investors consider latest...

Jan 5, 2017

Asian stock indexes mixed as investors assess latest Fed meeting minutes; Japan shares slip as yen...

China aircraft carrier capabilities tested on...

Jan 14, 2017

China's sole aircraft carrier has returned home following a three-week cruise during which its...

About Us

Frontal Report is an emerging leader in all forms of media. We aim to be the leading news brand for readers around the world.

Contact us: sales[at]frontalreport.com

Subscribe Now!